Alkixen (Crizotinib INN) 250 mg

0.00$

Alkixen, containing Crizotinib as its International Nonproprietary Name (INN), is primarily prescribed to treat non-small cell lung cancer (NSCLC), particularly in patients with specific genetic mutations like ALK-positive NSCLC. Acting as a potent inhibitor of ALK, Crizotinib targets the ALK protein commonly found in NSCLC cells, thereby hindering their proliferation. The standard dosage of Alkixen typically involves taking 250 mg orally twice daily, preferably with food. Possible side effects may include nausea, vomiting, diarrhea, fatigue, and visual disturbances. To effectively manage potential adverse effects and ensure favorable treatment outcomes, it is advisable to undergo regular medical evaluations and close monitoring during Alkixen therapy.

Add to wishlist
Share

    Indications: Alkixen (Crizotinib) 250 mg is prescribed for:

    • Treating non-small cell lung cancer (NSCLC) that expresses anaplastic lymphoma kinase (ALK).
    • Managing metastatic NSCLC in patients with tumors that are ROS1-positive.

    Pharmacology: Crizotinib is a tyrosine kinase inhibitor that works by blocking ALK, ROS1, and c-MET receptor tyrosine kinases. This action disrupts signaling pathways crucial for cancer cell growth and survival, thereby impeding tumor progression.

    Dosage and Administration: The recommended dose of Alkixen (Crizotinib) is 250 mg taken orally twice daily, with or without food. Dose adjustments may be necessary depending on individual patient responses and side effects.

    Interactions: Crizotinib may interact with other medications, hence patients should inform healthcare providers about all drugs being taken, including prescription, over-the-counter, vitamins, and herbal supplements.

    Side Effects: Common adverse effects of Alkixen (Crizotinib) include nausea, vomiting, diarrhea, constipation, fatigue, dizziness, vision disturbances, and abnormal liver function tests. More severe reactions may include interstitial lung disease, hepatotoxicity, and QT prolongation.

    Precautions and Warnings: Patients using Alkixen (Crizotinib) should be monitored for signs of interstitial lung disease, hepatotoxicity, and QT prolongation. Regular liver function tests and electrocardiograms may be necessary during treatment. Patients should also be informed about potential vision issues and advised against driving or operating machinery if affected.

    Overdose Effects: In the event of overdose, supportive measures are warranted. There is no specific antidote for Crizotinib overdose, and management should focus on addressing symptoms and providing supportive care.

    Product Name

    Alkixen

    Generic Name

    Crizotinib INN

    Formulation

    Capsule

    Available Pack size

    60 Capsules

    Strengths

    250 mg